NASDAQ:RGEN Repligen Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Repligen Co. Please log in to your account or sign up in order to add this asset to your watchlist. $166.52 +4.12 (+2.54%) (As of 07/1/2022 05:44 PM ET) Add Compare Share Today's Range$161.92▼$166.8150-Day Range$140.68▼$172.3652-Week Range$137.21▼$327.32Volume181,586 shsAverage Volume499,065 shsMarket Capitalization$9.06 billionP/E Ratio65.82Dividend YieldN/APrice Target$301.50 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Repligen Stock Forecast (MarketRank)Analyst RatingBuy3.00 Rating ScoreUpside/Downside81.1% Upside$301.50 Price TargetShort InterestBearish6.62% of Float Sold ShortDividend StrengthN/ASustainability-1.58Upright™ Environmental ScoreNews SentimentN/AInsider TradingSelling Shares$2.21 M Sold Last QuarterProj. Earnings Growth15.16%From $3.10 to $3.57 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.2.42 out of 5 starsMedical Sector120th out of 1,428 stocksBiological Products, Except Diagnostic Industry15th out of 217 stocks 3.5 Analyst's Opinion Consensus RatingRepligen has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $301.50, Repligen has a forecasted upside of 81.1% from its current price of $166.52.Amount of Analyst CoverageRepligen has received no research coverage in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted6.62% of the float of Repligen has been sold short.Short Interest Ratio / Days to CoverRepligen has a short interest ratio ("days to cover") of 4.8.Change versus previous monthShort interest in Repligen has recently decreased by 1.15%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldRepligen does not currently pay a dividend.Dividend GrowthRepligen does not have a long track record of dividend growth. Previous Next 3.3 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreRepligen has received a 58.17% net impact score from Upright. Repligen seems to create the most significant positive value in categories "Jobs", "Physical diseases", and "Taxes". The positive contribution in the "Physical diseases" impact category is mostly driven by its "Spin filters", "Protein gels", and "Chromatography columns" products. See details.Environmental SustainabilityThe Environmental Impact score for Repligen is -1.58. Previous Next 2.1 News and Social Media Coverage News SentimentRepligen has a news sentiment score of 0.71. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Repligen this week, compared to 4 articles on an average week.Search Interest5 people have searched for RGEN on MarketBeat in the last 30 days. This is an increase of 150% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added Repligen to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Repligen insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,214,755.00 in company stock.Percentage Held by InsidersOnly 1.10% of the stock of Repligen is held by insiders.Percentage Held by Institutions86.82% of the stock of Repligen is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Repligen are expected to grow by 15.16% in the coming year, from $3.10 to $3.57 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Repligen is 65.82, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 62.31.Price to Earnings Ratio vs. SectorThe P/E ratio of Repligen is 65.82, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 61.88.Price to Book Value per Share RatioRepligen has a P/B Ratio of 5.26. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive RGEN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Repligen and its competitors with MarketBeat's FREE daily newsletter. Email Address About Repligen (NASDAQ:RGEN)Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and SpectraFlo dynamic dialysis systems; and ProConnex single-use hollow fiber. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. Repligen Corporation was incorporated in 1981 and is headquartered in Waltham, Massachusetts.Read More RGEN Stock News HeadlinesJune 21, 2022 | americanbankingnews.comRepligen Co. (NASDAQ:RGEN) Given Consensus Recommendation of "Buy" by BrokeragesJune 16, 2022 | americanbankingnews.comOyster Point Pharma (NASDAQ:OYST) versus Repligen (NASDAQ:RGEN) Critical ContrastJuly 2, 2022 | Tradewins (Ad)The Safest Option in Trades!If you’re new to trading, then you’ve probably heard the wrong thing about options—that they’re risky, unpredictable, or difficult. And it couldn’t be more wrong! With the Hughes Optioneering Strategy, you’ll soon learn that the safest option for new accounts is options themselves! June 15, 2022 | americanbankingnews.comRepligen Co. (NASDAQ:RGEN) Forecasted to Earn FY2024 Earnings of $4.15 Per ShareJune 14, 2022 | finance.yahoo.comRepligen Corporation's (NASDAQ:RGEN) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?May 28, 2022 | finance.yahoo.comRepligen Appoints Dr. Konstantin Konstantinov to Board of Directors - Yahoo FinanceMay 27, 2022 | nasdaq.comRepligen (RGEN) Up 3.6% Since Last Earnings Report: Can It Continue? - NasdaqMay 27, 2022 | finance.yahoo.comRepligen (RGEN) Up 3.6% Since Last Earnings Report: Can It Continue?July 2, 2022 | Tradewins (Ad)The Safest Option in Trades!If you’re new to trading, then you’ve probably heard the wrong thing about options—that they’re risky, unpredictable, or difficult. And it couldn’t be more wrong! With the Hughes Optioneering Strategy, you’ll soon learn that the safest option for new accounts is options themselves! May 26, 2022 | globenewswire.comGlobal Biopharmaceutical Processing Equipment and Consumable Market to Witness Notable Growth of USD 78.02 Billion By 2030 : Fior Markets - GlobeNewswireMay 26, 2022 | globenewswire.comRepligen Appoints Dr. Konstantin Konstantinov to Board of Directors - GlobeNewswireMay 26, 2022 | benzinga.comRepligen Appoints Dr. Konstantin Konstantinov to Board of DirectorsMay 25, 2022 | globenewswire.comRepligen Corporation to Present at Upcoming Investor Conferences - GlobeNewswireMay 19, 2022 | fool.com2 Top Healthcare Stocks to Buy for the Long Haul - The Motley FoolMay 16, 2022 | nasdaq.comComparing Litecoin Versus Repligen Reveals New High - NasdaqMay 16, 2022 | finance.yahoo.comWill Repligen's (RGEN) COVID Woes Be Offset by Product Demand?May 12, 2022 | finance.yahoo.comWe Think Repligen (NASDAQ:RGEN) Can Manage Its Debt With EaseMay 11, 2022 | seekingalpha.comRevisiting Repligen - Seeking AlphaMay 6, 2022 | seekingalpha.comLRT Capital - Repligen Corporation: At The Exciting Frontiers Of Medicine - Seeking AlphaMay 5, 2022 | finance.yahoo.comIs it a Great Move to Invest in Repligen Corp. (RGEN)? - Yahoo FinanceMay 3, 2022 | finance.yahoo.comIs it a Great Move to Invest in Repligen Corp. (RGEN)?May 2, 2022 | benzinga.comRepligen's Return On Capital Employed Insights - Benzinga - BenzingaApril 28, 2022 | finance.yahoo.comRepligen (RGEN) Q1 Earnings and Sales Beat Estimates, Stock UpApril 28, 2022 | benzinga.comSVB Leerink Maintains Outperform on Repligen, Lowers Price Target to $220 - Benzinga - BenzingaApril 28, 2022 | benzinga.comKeybanc Maintains Overweight on Repligen, Lowers Price Target to $245 - Benzinga - BenzingaApril 27, 2022 | benzinga.comRepligen shares are trading higher after the company reported better-than-expected Q1 EPS and sales resul - BenzingaApril 27, 2022 | benzinga.comRecap: Repligen Q1 Earnings - BenzingaSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:RGEN CUSIP75991610 CIK730272 Webwww.repligen.com Phone(781) 250-0111Fax781-250-0115Employees1,852Year Founded1981Company Calendar Last Earnings4/27/2022Today7/02/2022Next Earnings (Estimated)7/26/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$301.50 High Stock Price Forecast$335.00 Low Stock Price Forecast$250.00 Forecasted Upside/Downside+81.1%Consensus RatingBuy Rating Score (0-4)3 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)$2.529990 Trailing P/E Ratio65.82 Forward P/E Ratio53.72 P/E GrowthN/ANet Income$128.29 million Net Margins19.86% Pretax Margin24.43% Return on Equity11.13% Return on Assets8.46% Debt Debt-to-Equity RatioN/A Current Ratio2.23 Quick Ratio1.72 Sales & Book Value Annual Sales$670.53 million Price / Sales13.52 Cash Flow$4.09 per share Price / Cash Flow40.72 Book Value$31.65 per share Price / Book5.26Miscellaneous Outstanding Shares54,429,000Free Float53,830,000Market Cap$9.06 billion OptionableOptionable Beta0.98 Social Links Repligen Frequently Asked Questions Should I buy or sell Repligen stock right now? 6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Repligen in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Repligen stock. View analyst ratings for Repligen or view top-rated stocks. What is Repligen's stock price forecast for 2022? 6 Wall Street analysts have issued 1-year price targets for Repligen's stock. Their RGEN stock forecasts range from $250.00 to $335.00. On average, they predict Repligen's stock price to reach $301.50 in the next twelve months. This suggests a possible upside of 81.1% from the stock's current price. View analysts' price targets for Repligen or view top-rated stocks among Wall Street analysts. How has Repligen's stock performed in 2022? Repligen's stock was trading at $264.84 at the beginning of the year. Since then, RGEN shares have decreased by 37.1% and is now trading at $166.52. View the best growth stocks for 2022 here. When is Repligen's next earnings date? Repligen is scheduled to release its next quarterly earnings announcement on Tuesday, July 26th 2022. View our earnings forecast for Repligen. How were Repligen's earnings last quarter? Repligen Co. (NASDAQ:RGEN) released its quarterly earnings results on Wednesday, April, 27th. The biotechnology company reported $0.92 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.72 by $0.20. The biotechnology company earned $206.40 million during the quarter, compared to analyst estimates of $185.48 million. Repligen had a net margin of 19.86% and a trailing twelve-month return on equity of 11.13%. The company's quarterly revenue was up 44.5% on a year-over-year basis. During the same period last year, the company posted $0.68 EPS. View Repligen's earnings history. What guidance has Repligen issued on next quarter's earnings? Repligen issued an update on its FY22 earnings guidance on Wednesday, April, 27th. The company provided earnings per share guidance of $3.07-3.15 for the period, compared to the consensus EPS estimate of $3.25. The company issued revenue guidance of $770-800 million, compared to the consensus revenue estimate of $820.31 million. Who are Repligen's key executives? Repligen's management team includes the following people: Mr. Anthony J. Hunt, Pres, CEO & Director (Age 58, Pay $2.1M) (LinkedIn Profile)Mr. Jon K. Snodgres, Chief Financial Officer (Age 56, Pay $860.08k) (LinkedIn Profile)Mr. James R. Bylund, Chief Operating Officer (Age 58, Pay $725.55k) (LinkedIn Profile)Ms. Christine Gebski, Sr. VP of Filtration & Chromatography (Age 53, Pay $685.06k) (LinkedIn Profile)Mr. Ralf Kuriyel, Sr. VP of R&D (Age 63, Pay $708.15k) (LinkedIn Profile)Ms. Sondra S. Newman, Global Head of Investor RelationsMs. Kimberly Cornwell, Global Head of Legal & Gen. CounselMr. Stephen Tingley, VP & Head of Global SalesMs. Rachel Goodrich, VP of MarketingMr. Ken Elmer, Global Head of HR What is Tony J. Hunt's approval rating as Repligen's CEO? 13 employees have rated Repligen CEO Tony J. Hunt on Glassdoor.com. Tony J. Hunt has an approval rating of 52% among Repligen's employees. This puts Tony J. Hunt in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. Who are some of Repligen's key competitors? Some companies that are related to Repligen include Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Seagen (SGEN), Biogen (BIIB), Alnylam Pharmaceuticals (ALNY), Incyte (INCY), BioMarin Pharmaceutical (BMRN), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX), Exact Sciences (EXAS), Exelixis (EXEL), Halozyme Therapeutics (HALO) and Ionis Pharmaceuticals (IONS). View all of RGEN's competitors. What other stocks do shareholders of Repligen own? Based on aggregate information from My MarketBeat watchlists, some companies that other Repligen investors own include NVIDIA (NVDA), Alibaba Group (BABA), Salesforce (CRM), Square (SQ), Advanced Micro Devices (AMD), DocuSign (DOCU), Walt Disney (DIS), Netflix (NFLX), Tesla (TSLA) and ServiceNow (NOW). What is Repligen's stock symbol? Repligen trades on the NASDAQ under the ticker symbol "RGEN." How do I buy shares of Repligen? Shares of RGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Repligen's stock price today? One share of RGEN stock can currently be purchased for approximately $166.52. How much money does Repligen make? Repligen (NASDAQ:RGEN) has a market capitalization of $9.06 billion and generates $670.53 million in revenue each year. The biotechnology company earns $128.29 million in net income (profit) each year or $2.529990 on an earnings per share basis. How many employees does Repligen have? Repligen employs 1,852 workers across the globe. Does Repligen have any subsidiaries? The following companies are subsidiares of Repligen: ARTeSYN Biosolutions Holdings Ireland Limite, C Technologies Inc., Engineered Molding Technology LLC, Non-Metallic Solutions Inc, Repligen (Shanghai) Biotechnology Co. Ltd., Repligen Europe B.V., Repligen GmbH, Repligen India Private Limited, Repligen Japan LLC, Repligen Korea Co. Ltd., Repligen Singapore Pte. Ltd., Repligen Sweden AB, and Spectrum Lifesciences LLC.Read More When was Repligen founded? Repligen was founded in 1981. How can I contact Repligen? Repligen's mailing address is 41 SEYON STREET BUILDING 1 SUITE 100, WALTHAM MA, 02453. The official website for Repligen is www.repligen.com. The biotechnology company can be reached via phone at (781) 250-0111, via email at investors@repligen.com, or via fax at 781-250-0115. This page (NASDAQ:RGEN) was last updated on 7/2/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here